JAK2 Specificity and Thrombosis Risk: Potential Role of Antiphospholipid Antibodies

REFERENCES

1. 1.↵
   1. Keystone EC,
   2. Genovese MC,
   3. Schlichting DE,
   4. de la Torre I,
   5. Beattie SD,
   6. Rooney TP,
   7. et al.

   Safety and efficacy of baricitinib through 128 weeks in an open-label, longterm extension study in patients with rheumatoid arthritis. J Rheumatol 2018;45:14–21.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Alicea-Velázquez NL,
   2. Boggon TJ

   . The use of structural biology in Janus kinase targeted drug discovery. Curr Drug Targets 2011;12:546–55.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Huizinga TW,
   2. Kay J,
   3. Harigai M,
   4. Keystone E,
   5. Smolen J,
   6. Rosas J,
   7. et al.

   Effects of baricitinib on haematological laboratory parameters in patients with rheumatoid arthritis [abstract]. Rheumatology 2018;57 Suppl 3: key075.589.

   OpenUrl
4. 4.↵
   1. Keystone EC,
   2. Taylor PC,
   3. Drescher E,
   4. Schlichting DE,
   5. Beattie SD,
   6. Berclaz PY,
   7. et al.

   Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have an inadequate response to methotrexate. Ann Rheum Dis 2015;74:333–40.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. O’Shea JJ

   . Targeting the Jak/STAT pathway for immunosuppression. Ann Rheum Dis 2004;63 Suppl 2:ii67–71.

   OpenUrlFREE Full Text
6. 6.↵
   1. Cohen D,
   2. Berger SP,
   3. Steup-Beekman GM,
   4. Bloemenkamp KW,
   5. Bajema IM

   . Diagnosis and management of the antiphospholipid syndrome. BMJ 2010;340:2541.

   OpenUrl
7. 7.↵
   1. Yalavarthi S,
   2. Gould TJ,
   3. Rao AN,
   4. Mazza LF,
   5. Morris AE,
   6. Núñez-Alvarez C,
   7. et al.

   Release of neutrophil extracellular traps by neutrophils stimulated with antiphospholipid antibodies: a newly identified mechanism of thrombosis in the antiphospholipid syndrome. Arthritis Rheumol 2015;67:2990–3003.

   OpenUrl
8. 8.↵
   1. Khamashta MA,
   2. Cuadrado MJ,
   3. Mujic F,
   4. Taub NA,
   5. Hunt BJ,
   6. Hughes GR

   . The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995;332:993–7.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Rothschild BM

   . Comparative antiplatelet activity of COX1 NSAIDS versus aspirin, encompassing regimen simplification and gastroprotection: a call for a controlled study. Reumatismo 2004;56:89–93.

   OpenUrlPubMed